This site is intended for health professionals only

Sanofi-Aventis buys BiPar Sciences

teaser

A radical new cancer drug is behind the $500 million (£335 million) purchase of California-based BiPar Sciences by Paris-based Sanofi-Aventis.

Known as BSI-201, the BiPara treatment is a PARP (poly ADP-ribose polymerase) inhibitor that targets molecular processes critical for the growth and proliferation of cancer cells.

It is currently being evaluated in phase 2 clinical trials in triple negative breast cancer, ovarian cancer and other solid-tumour cancers.

The Sanofi deal is the latest in a string of worldwide acquisitions by the company, including generic-drug-maker Medley, Brazil’s third-largest pharmaceutical company, and Laboratorios Kendrick, a Mexican generic drug maker.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

The driver behind those two deals is a major US boost in the sale of generic drugs, which cost 30% to 80% less than the original brand-names, according to the Generic Pharmaceutical Association.

As the global recession has deepened, the number of prescriptions for generic drugs has jumped by 8%, now accounting for 68% of all prescriptions in the US.

Copyright Press Association 2009

BiPar






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x